Bone marrow-specific deletion of TET2 or DNMT3A is associated with cardiac hypertrophy, fibrosis and impaired LV fractional shortening after infusion of angiotensin II in comparison with WT controls [107]. This evidence concerns the gene DNMT3A and cardiac hypertrophy.